Compare GSK plc (GSK) vs VanEck Vietnam ETF (VNM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs VanEck Vietnam ETF — how do they compare? GSK plc trades at $46.52 (market cap $91.88B), while VanEck Vietnam ETF trades at $16.74 (market cap $469.76M). The key difference: GSK plc is far larger — about 195.6× VanEck Vietnam ETF's market cap, and GSK plc pays a 3.9% dividend while VanEck Vietnam ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and VanEck Vietnam ETF for 51 Days on average.
| GSK | VNM | |
|---|---|---|
Market Cap | $91.88B | $469.76M |
Volume | 7,730,529 | 375,157 |
Sector | Health | Sector/Thematic |
52-Week High | $61.18 | $19.80 |
52-Week Low | $43.24 | $16.34 |
Typical Hold Time | 93 Days | 51 Days |
Enterprise Value | $111.88B | — |
Dividend Yield | 3.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.50, down 1.11% with bearish technical signals, though RSI levels suggest potential oversold conditions. Fundamentally, the company shows strong profitability with 72.73% gross margins and consistent earnings beats, while maintaining a reasonable P/E of 14.89. Recent developments include strategic oncology partnerships and a $750M cancer therapy acquisition, positioning for long-term growth despite facing an HIV patent cliff.
GSK presents a mixed investment case with strong fundamentals and pipeline growth offset by technical weakness and patent expiration risks. The company's £40B sales target and cost-saving initiatives provide upside potential, while analyst consensus leans cautious with 55% hold ratings. Key risks include execution of pipeline development and competitive pressures in core markets.
VNM trades at $16.72, down 0.89% today, with a bearish technical signal from moving averages but bullish momentum from oscillators. The stock faces sector concentration risks in real estate and financials while benefiting from Vietnam's potential US trade deal progress. Key support and resistance cluster around $17, with RSI levels indicating potential oversold conditions.
The outlook remains cautious due to sector headwinds and interest rate sensitivity, though fair valuation and macroeconomic growth prospects offer long-term potential. Near-term performance depends on trade developments and sector stability, with institutional sentiment mixed on timing and risk exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About VanEck Vietnam ETF
VNM is the first and largest U.S.-listed ETF providing targeted exposure to the Vietnamese equity market. It tracks the MarketVector™ Vietnam Local Index, which includes publicly traded companies that are locally incorporated in Vietnam. It serves as a liquid, transparent vehicle for investors looking to participate in Vietnam's transition into a global manufacturing hub and its long-term potential for emerging market reclassification.
Read more on VNM →
